TY  - JOUR
AU  - Scheen, André J.
PY  - 2018
TI  - Effect of sodium-glucose cotransporter type 2 inhibitors on liver  fat in patients with type 2 diabetes: hepatic beyond cardiovascular  and renal protection?
JF  - Annals of Translational Medicine; Vol 6, Supplement 1 (November 29, 2018): Annals of Translational Medicine
Y2  - 2018
KW  - 
N2  - Non-alcoholic fatty liver disease (NAFLD) is a common finding in obese people, especially patients with type 2 diabetes (T2DM). It may progress to non-alcoholic steatohepatitis (NASH) and ultimately fibrosis and cirrhosis (1-3). Because of the epidemics of both obesity and T2DM, the prevalence of NAFLD will increase, potentially causing a tremendous clinical and economic burden (4).
UR  - https://atm.amegroups.org/article/view/22036